¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º  W|6.gN ]  
}S9uh-j6l  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ u]<`y6=&C  
h}%yG{'/M=  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) [jF\"#A  
9-?kamA  
1. ICAM-1 %/wfYRp*  
^j'vM\^`ml  
2. interleukin 12(IL-12) @TnAO8Q>XD  
7 P]Sc   
3. tumor infiltrating lymphocyte =_d-MJy~6  
MP`WU}2  
4. TCR/CD3 complex m}nA- *  
\8S HX  
5. hematopoietin receptor family k N$L8U8f  
&?7+8n&+  
6. individual idiotype(IdI) Xc Q'(  
_xXDvBU  
7. integrin bq` 0$c%hN  
%LZf= `:(  
8. colony-stimulatory factor (CSF) 2BIOA#@t  
~ TALpd  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© zgHF-KEV  
qxglA*/ [  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? '^.}5be&  
!P b39[f  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ 5VPP 2;J  
pxs`g&3yd  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠT1r^.;I:  
o*WI*Fb'  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ k`Ifd:V.y  
: S |)  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) ZN?UkFnE  
dq ~=P>  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ t Sf`  
g:nU&-x#R  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) ?QXo]X;f&  
a<K@rgQ  
3. immunoglobulin superfamily (IgSF) ~8G<Nw4*\  
nY<hfqof  
4. selectin ?(CMm%(8  
fX2PteA0qX  
5. anti-idiotypic antibody (¦ÁId) AyMMr_q  
Ng3MfbFG  
6. major histocompatibility complex(MHC) (_ElM >  
)d6Ya1vJH  
7. immunotolerance Y +tXWN"8  
8y{<M"v+/  
8. biological reponse modifier(BRM) NwdA@"YQ|  
eOQUy +  
9. immune reponse gene (Ir gene) )5 j%."  
f9g#pyH4  
10. reshaped antibody (or reconstituted antibody) A8R}W=  
[$Ld>`3  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ##!) }i  
cFoDR  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ RYaf{i`  
V(Ps6jR"BS  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? g(Jzu'  
j#b?P=|l  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ $3sS&i<  
vb}; _/ #?  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? XnQo0 R.PW  
<m80e),~  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ }xHoitOD  
m[C-/f^u|  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? yk9|H)-z  
W$0<a@  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ j3rBEQ,R  
-tSWYp{  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ PY.c$)az>  
l'(Cxhf.W  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? Te~"\`omJ3  
m u(HNj  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ W 0Q-&4  
|$":7)e H!  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: Ay!=Yk ^~  
z_eP  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: [SgP1>M  
#"6(Q2| l  
ÃâÒßѧ &3>ki0L  
>>wb yj8  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 2s;/*<WM  
[zK|OMxoV  
1. CD8 9tXLC|yl?  
f 5_n 2  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) Nm#VA.~  
,:QG%Et  
3. immunoglobulin fold(Ig fold) \i "I1xU  
 "= H7p3  
4. cadherin (Ca-dependent cell adhesion moleculers) 52tIe|KwL  
=V_} z3b  
5. idiotype-anti-idiotypic antibody immune network theory \*!?\Ko`W  
EKk~~PhW 8  
6. HLA class II antigen AShJt xxa  
R* E/E  
7. complementarity-determining region (CDR) NyJU?^f&v  
XY1NTo. =  
8. perforin(or pore-forming protein ,PFP) vyERt^z  
pQ*9)C   
9. high affinity IL-2 receptor E$34myOVf  
e\k=T }  
10. artificial active immunization [L|H1ll  
+e%9P%[+  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©  e1S |&W8  
R(=Lhz6R4  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ,`G8U/  
i15uHl  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 2K!3+D"  
kW4/0PD  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ y;yXOE_  
7tfMD(Q]e/  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ yd`xmc)  
qWHH% L;  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ *|Q'?ty(x  
?a7PxD.  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? >,y291p2  
K\nN2y  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 5.]+K<:h"A  
xSs);XO,  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ gtyo~f  
-f#0$Z/0  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 7!#x-KR~5  
wP/&k`HQ#i  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ tlV>  
n&D< l '4  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© F.HD;C-;(  
,@tkL!"9q  
1. immunoglobulin gene rearrangement <h4"^9hL  
=zDU!< U  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) ^rfY9qMJr8  
L$cNxz0$  
3. flow cytometry(FCM) UZi^ &  
%2f``48#  
4. carrier effect y{,HpPp#o  
X]U,`oE)9  
5. positive selection of T lymphocytes in thymus hF s:9  
KoRJ'WW^  
6. mouse TH1(Th1) and TH2(Th2) subsets &M,a+|yuY  
rIH/<@+  
7. perforin (pore-forming protein ,PFP) gS_)(  
t 9&xk?%{  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) rmu5K$pl  
_G|hKk^,  
9. SH-2(src-homology region 2) HYyO/U9z|I  
E0!}~Z)  
10. Ab2¦Â (internal image) K#rfQ0QK/!  
S<rdPS*P  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© SeN4gr*  
oG M Ls  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? Q1jU{  
$h`(toTyF  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? '9c`[^  
:K>v F`SM  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ[bk2RaX:i  
t ~ruP',~\  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ 1 rKKph  
R*a5bKr  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠdU1w)Y  
$R(?@B(  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) |z\5Ik!fF]  
wI><kdz  
ÃâÒßѧרҵ£º ,@kD9n5#  
mR@|]T  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ tvXoF;Yq  
^]l^q'?>:  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? fZ1v|  
qzS 9ls>>  
´«È¾²¡Ñ§×¨Òµ£º rC fr&>nn  
J!5BH2bg  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ _OV\W'RrA  
OzY55  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ Atsi}zTR\  
g?N~mca$  
Ïû»¯×¨Òµ£º Ot}fGiio  
WeDeD\zy  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ ^7M hnA  
e~R; 2bk  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ?  *z[G+JX  
zvjVM"=G  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ L[ l ?}\  
%pj 6[x`@  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© MV +R$  
-c-af%xD  
1. Fas(CD95)/FasL 2VmQ%y6e"  
vSty.:bY\p  
2. common chain of cytokine receptor J)1:jieQ  
UjibQl 3:m  
3 . TCR/CD3 complex uC\FW6K=m  
u8ofg cFYE  
4. negaive selection of thymocytes @X`~r8&  
d"3S[_U  
5. artificial active immune jVP70c  
LhM{LUi  
6. anti-idiotypic Jf\lnJTyU8  
d:/8P985  
7. IgSF ").MU[q%Y  
NGYliP,.6  
8. Integrin xlPUu m-o  
TU ]Ed*'&  
9. chemokine o `?0D)/O  
}~P%S(zB  
10. B7/CD28 [8*Ovd  
gfE<XrG  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© d,=Kv  
n^|;J*rD  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ 1-Fg_G}|6  
34VyR a  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ ;t47cUm6j  
J6x\_]1:*  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ R'a%_sACj>  
 Q(SVJ  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ xt]Z{:.  
\8\)5#?  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ Oq"(oNG@  
~82[pY  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ fr'M)ox1  
{#q']YDe`  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© `mPmEV<  
'^'4C'J  
1. B7/CD28 Tks;,C  
"cjZ6^Hum  
2. Th1 subset H e]1 <tx  
3_=~7B) 8  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© $,08y   
L/(e/Jalg  
4. antibody affinity maturation k hT&[!J{>  
o D;  
5. AP-1 !8&,GT  
;ak3 @Uee  
6. single chain variable fragment£¨ScFv£© ulFU(%&  
#oMbE<//"  
7. NK cell receptor 9 [DQ[bL  
~\dpD  
8. Zinkernagel-Doherty phenomenon LLmgk"  
475yX-A  
9. Ig fold rh2pVDS  
i]GBu  
10. CD40/CD40L lp[3z& u  
($(6]?J(?7  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© 322W"qduTZ  
(Br$(XJoK}  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ cb&y8!ci~  
j5z, l  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ Y^LFJB|b4  
1W~-C B>  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ j>&n5?  
M Ia].S#  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ EC1q#;:  
Te'^O,C)y$  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ xy  mK|  
a2/r$Tgm  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ s cR-|GuZ  
js`zQx'  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ @usQ*k  
|L;'In  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© CW\o>yh  
I#eIm3Y?  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© O RQGay  
6?*iIA$b  
1.Co-stimulators (or co-stimulating molecules) 3\=8tg p  
!P@u4FCs  
2.NK-kB <eN>X:_N  
?P`wLS^;  
3.Immunoglobulin superfamily >[|:cz  
EoU}@MjM~  
4.antigen-presenting cell (APC) gY0*u+LF  
Jr17pu(t  
5.death domain 2IjqT L  
rA=F:N 2  
6.CCR and CXCR 7/Lbs  
! FHNKh  
7.Lectin (or mitogen) "6Dz~5  
oPa2GW8  
8.Clusters of differentiation, CD) hNx`=D9[7  
pbqa  
9.B7 family BOwkC;Q[  
,}{E+e5jh7  
10.Cytotoxic T lymphocyte, CTL) -^#Ix;%  
>5^Z'!Z"  
11.IL-15 and IL-15 receptor (IL-15R) E/U1g4S  
O')Ivm,E  
12.MHC restriction bO2$0!=I  
[j93Mp  
13.Affinity-chromatography @Wx_4LOhf  
~]"}s(J;  
14.Cyctosprin A, CsA TP^.]I O-  
8l='Hl  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) Mm6 (Q  
%{}Jr`  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© sgCIY:8  
+,|-4U@dl  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 aaaC8;.  
l>=c]  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ,YkQJ$  
cOUO_xp(  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ RIJBHOa  
|xf%1(Rl@  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© gcv,]v 8  
*:&fw'vd,  
ÃâÒßѧרҵ£º ]AHUo;(f%  
o1n c.2/0J  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ {X"X.`p  
+ u)'  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 2<988F  
Aga7X @fV(  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ hG ] jm  
. }=;]=  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) Z2$-},i  
Hv`Zc*  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 3; M!]9ms  
*Z0}0< D@Z  
1. ADCC(antibody dependent cell-mediated cytotoxicity) u(~s$EN l  
:5Vu.\,1  
2. »·æß¾úËØ(cyclosporin) 9z-"JnM  
\ agC Q&  
3. KIR(killer cell inhibitory receptor) h]=chz  
rcbixOT  
4. HLDA(human leucocyte differentiation antigen) ~Ep&:c4:D  
y~dW=zO  
5. Interleukin 18(IL-18) vx4& ;2  
m: ^@AR1%d  
6. ÕûºÏËØ(integrin) 'v,W gPe  
dHu]wog  
7. Fas/FasL ]MHQ "E?  
t #AQD]h  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) vbFAS:Y:+  
dqe_&C@*O  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) H}@|ucM"\  
*H$nydQ:  
10. Th1/Th2 ~\/ J&  
J^XH^`'  
11. »ùÒòÒßÃç(DNAÒßÃç) T-@pTJ !K9  
63f/-64?7  
12. chemokines and chemokine receptor G'epsD,.bX  
u1"e+4f  
13. ÃâÒßÄÍÊÜ :.~a[\C@V<  
IQ_0[  
14. ¹²´Ì¼¤·Ö×Ó WLpn,8qsY  
/X:lt^?%I  
15. ËÀÍö½á¹¹Óò(death domain) MPB6  
VgdkCdWRm_  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) ;L[9[uQ[C  
I45A$nV#Q  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? `%=Jsi0.Nq  
cC[n~OV  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠe%P;Jj476  
H>r-|*n  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î ZChY:I$<  
WY,t> 1c  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ Fv: %"P^  
98]t"ny [  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå H>] z=w~  
Rf^cw}jU  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ qIT{`hX  
u s0'7|{q  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) c 2@@Rd~M  
 =s]{  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 8_m9CQ6 i  
kn"x[{d  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ aX%Zuyny  
h %s  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»